India Strengthens Regulation of GLP-1 Weight Loss Drug Supply Chain India’s drug regulatory authority has intensified its oversight of the distribution and use of GLP-1-based weight loss medications, launching a nationwide enforcement campaign to address illegal activities and ensure compliance with safety standards. The Central Drugs Standard Control Organisation (CDSCO), working alongside state Licensing Authorities (SLAs), has conducted comprehensive inspections and audits across multiple regions to target non-compliant practices, including improper dispensing and misuse of these drugs. The initiative aims to reinforce adherence to the conditions of approval and label warnings for GLP-1-based weight loss treatments. State drug controllers have been directed to enhance monitoring of the entire supply chain, from manufacturing to retail, to prevent unauthorized distribution. Authorities are also urged to collaborate with the Advertising Standards Council of India (ASCI) and other relevant bodies to ensure strict enforcement of regulations. Over the past several weeks, the campaign has focused on identifying and addressing violations in the distribution chain, which has raised concerns about the potential risks associated with these medications. The enforcement efforts include coordinated inspections of pharmacies, healthcare providers, and other entities involved in the supply of GLP-1 drugs. The regulator emphasized the need for strict compliance to protect public health and prevent the proliferation of counterfeit or substandard products. The move comes amid growing scrutiny of GLP-1 drugs, which have gained popularity for their effectiveness in weight management but also face challenges related to accessibility and misuse.#advertising_standards_council_of_india #pharmaceutical_sector #glp_1_drugs #central_drugs_standard_control_organisation #state_licensing_authorities
Hrithik Roshan Today, March 15: Jhalawar Court Sets April 10 Hearing A consumer court in Jhalawar has scheduled a hearing for April 10 regarding a complaint against a Mountain Dew advertisement featuring actor Hrithik Roshan. The case centers on allegations that the ad’s promotional language exaggerates energy-related claims, potentially misleading viewers. Legal filings indicate that the defense has submitted its response, and a plea has been made to temporarily halt the ad’s broadcast while the case proceeds. The court’s next scheduled session will address these issues, with the actor’s legal team and the complainant both seeking interim measures to pause the ad’s airing. The complaint argues that the ad’s punchy, motivational lines could be interpreted as literal promises of enhanced energy or performance, raising concerns about the accuracy of the claims. The defense has acknowledged the allegations but has not yet provided specific rebuttals. The court is expected to determine whether the ad’s messaging violates India’s advertising regulations, which require celebrities to ensure claims are substantiated and clearly communicated. A potential ruling could result in edits, takedowns, or corrective measures for the ad, adding costs and delays for the brand. India’s advertising standards, governed by the Advertising Standards Council of India (ASCI), mandate that celebrities and advertisers verify claims and include visible disclaimers. Advertisers often conduct testing, consumer perception checks, and legal reviews to comply with these rules. If the court finds the Mountain Dew ad non-compliant, it could trigger additional expenses for the brand, including reshoots, post-production changes, and the creation of alternate ad versions.#hrithik_roshan #mountain_dew #jhalawar_court #advertising_standards_council_of_india #ascci
